Open access · CC-BY
via OpenAlex
GBA Variants and Parkinson Disease: Mechanisms and Treatments
Laura Smith, Anthony H.V. Schapira
Cells · 2022 · ▲ 260 citations
Abstract
The GBA gene encodes for the lysosomal enzyme glucocerebrosidase (GCase), which maintains glycosphingolipid homeostasis. Approximately 5–15% of PD patients have mutations in the GBA gene, making it numerically the most important genetic risk factor for Parkinson disease (PD). Clinically, GBA-associated PD is identical to sporadic PD, aside from the earlier age at onset (AAO), more frequent cognitive impairment and more rapid progression. Mutations in GBA can be associated with loss- and gain-of-function mechanisms. A key hallmark of PD is the presence of intraneuronal proteinaceous inclusions named Lewy bodies, which are made up primarily of alpha-synuclein. Mutations in the GBA gene may lead to loss of GCase activity and lysosomal dysfunction, which may impair alpha-synuclein metabolism. Models of GCase deficiency demonstrate dysfunction of the autophagic-lysosomal pathway and subsequent accumulation of alpha-synuclein. This dysfunction can also lead to aberrant lipid metabolism, including the accumulation of glycosphingolipids, glucosylceramide and glucosylsphingosine. Certain mutations cause GCase to be misfolded and retained in the endoplasmic reticulum (ER), activating stress responses including the unfolded protein response (UPR), which may contribute to neurodegeneration. In addition to these mechanisms, a GCase deficiency has also been associated with mitochondrial dysfunction(definition) and neuroinflammation, which have been implicated in the pathogenesis of PD. This review discusses the pathways associated with GBA-PD and highlights potential treatments which may act to target GCase and prevent neurodegeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/cells11081261
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Smith, L., & Schapira, A.H. (2022). GBA Variants and Parkinson Disease: Mechanisms and Treatments. <em>Cells</em>. https://doi.org/10.3390/cells11081261
Vancouver
Smith L, Schapira AH. GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells. 2022. doi:10.3390/cells11081261.
BibTeX
@article{laura2022GBAVar,
title = {GBA Variants and Parkinson Disease: Mechanisms and Treatments},
author = {Laura Smith and Anthony H.V. Schapira},
journal = {Cells},
year = {2022},
doi = {10.3390/cells11081261},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ageing Research Reviews 2017
Citation only
Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson’s disease. An integrated strategy for management
Journal of Neurochemistry 2016
Open access · OA
Mitochondrial dysfunction in Parkinson's disease
Aging and Disease 2016
Open access · CC-BY
Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies
Molecular Neurodegeneration 2023
Open access · CC-BY
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Alzheimer s & Dementia 2025
Open access · CC-BY
Diabetic retinopathy and Alzheimer's disease: Convergence of the unfolded protein response in neurodegeneration
Frontiers in Cellular Neuroscience 2020
Open access · CC-BY